Xinming Ye

Dr. Xinming Ye


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2026 in Translational Oncology
Verified
Journal Article
Open access
WFWen Fang
Wen Fang
YWYang Wu
Yang Wu
ZYZhenyu Yang
Zhenyu Yang
HZHongyun Zheng
Hongyun Zheng
MTMenghao Tang
Menghao Tang
XYXinming Ye
Xinming Ye
Marked interindividual variability in cancer treatment outcomes indicates that traditional strategies focused solely on direct tumor cell eradication are insufficient to explain real world clinical responses. Host responsiveness to therapeutic stimuli has emerged as a critical determinant of efficacy. In recent years, the gut microbiota has been recognized as a central regulatory hub linking host immune and metabolic states with treatment outcomes. Through systemic modulation of immune activation thresholds, inflammatory tone, and tissue repair capacity, microbiota function participates deeply in shaping responses to immunotherapy, chemotherapy, and radiotherapy. Against the background of safety, stability, and personalization constraints associated with existing microbiota interventions, exercise has gained attention as a controllable endogenous physiological stimulus with long term feasibility. Regular physical activity reshapes the host metabolic milieu, strengthens intestinal barrier integrity, reduces basal systemic inflammation, and stabilizes immune homeostasis, thereby promoting a microbiota functional state that supports antitumor immunity. In this context, the host environment shifts from a passive background factor to an actively optimizable therapeutic variable. The regulatory axis formed by interactions between exercise and the gut microbiota provides a novel biological perspective for understanding treatment response heterogeneity across modalities and offers a unified functional rationale for enhancing immunotherapy responsiveness, improving chemotherapy tolerance, and facilitating radiotherapy associated tissue repair. Overall, integrating exercise into a host responsiveness centered therapeutic framework holds promise for amplifying treatment efficacy and improving long-term outcomes without altering existing oncologic regimens. With standardized study designs, refined functional assessment systems, and strengthened multidisciplinary collaboration, exercise mediated microbiota modulation is expected to progress from mechanistic exploration toward clinical implementation and become an integral component of comprehensive cancer therapy.

18 August 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
WFWen Fang
Wen Fang
YWYihan Wang
Yihan Wang
ZYZhenyu Yang
Zhenyu Yang
HZHongyun Zheng
Hongyun Zheng
YWYang Wu
Yang Wu
XYXinming Ye
Xinming Ye
Cancer in older adults has become a significant public health challenge, with increasing incidence and limited efficacy of conventional treatments due to aging-related biological changes, such as chronic inflammation, immune decline, metabolic dysfunction, and cellular senescence. These alterations create a pro-tumor environment, weakening antitumor capacity and reducing treatment sensitivity. Exercise medicine has emerged as a promising systemic intervention, regulating multiple physiological systems, including metabolism, immunity, skeletal muscle, and inflammation. Through these effects, exercise reshapes the aging-driven tumor-susceptible environment, potentially improving treatment tolerability and clinical outcomes. This review explores how exercise alleviates aging-associated phenotypes like metabolic decline, chronic inflammation, immune dysfunction, and sarcopenia, enhancing tumor suppression and boosting the efficacy of chemotherapy, radiotherapy, and immunotherapy. It also discusses strategies for precision exercise interventions, such as individualized prescriptions based on aging biomarkers, comprehensive risk assessments, safety management, multidisciplinary collaboration, and digital monitoring technologies. This review highlights the importance of integrating exercise into geriatric oncology care and outlines future research directions to improve the clinical management of cancer in older adults.

13 November 2026 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
RWRuilong Wang
Ruilong Wang
HZHongyun Zheng
Hongyun Zheng
AZAnzhou Zhu
Anzhou Zhu
YCYicong Cui
Yicong Cui
YLyuan li
yuan li
XYXinming Ye
Xinming Ye
Cognitive decline in older adults can affect memory, attention, executive control, processing speed, and working memory, with consequences for everyday fun

7 July 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JWJing Wang
Jing Wang
ZYZhenyu Yang
Zhenyu Yang
YWYang Wu
Yang Wu
MTMenghao Tang
Menghao Tang
YWYihan Wang
Yihan Wang
MDMei Du
Mei Du
Effective treatment of endometrial cancer (EC) is frequently challenged by therapeutic resistance, immunosuppressive tumor microenvironments (TME), and patient comorbidities such as hypertension, kidney dysfunction, and metabolic syndrome. While molecular targeted therapies and immunotherapies (e.g., PD-1 blockade) have emerged as transformative approaches, variable drug sensitivity—often exacerbated by the systemic inflammatory and uremic burden of comorbidities—remains a significant hurdle. Building on the integration of molecular oncology and clinical translation, this review examines physical activity not merely as a preventive measure, but as a systems-level molecular modulator capable of enhancing drug sensitivity and immunotherapy efficacy. We synthesize evidence distinguishing preclinical findings from clinical reality, demonstrating that exercise remodels the TME by repolarizing Tumor-Associated Macrophages (TAMs), reducing Myeloid-Derived Suppressor Cells (MDSCs), and enhancing cytotoxic T cell infiltration. Furthermore, we discuss how exercise-induced shear stress promotes eNOS phosphorylation to normalize tumor vasculature and improve renal perfusion, thereby enhancing drug delivery and mitigating nephrotoxicity. We propose an integrated “EC-Comorbidity Continuum” perspective where personalized exercise prescriptions—distinguishing between acute perfusion benefits and chronic immune priming—serve as a non-pharmacological adjuvant to optimize molecular responses and overcome multidrug resistance.

3 July 2026 in Translational Oncology
Verified
Journal Article
Open access
ZLZeng Li
Zeng Li
XDXiaotong Du
Xiaotong Du
ZYZhenyu Yang
Zhenyu Yang
YWYang Wu
Yang Wu
MTMenghao Tang
Menghao Tang
XYXinming Ye
Xinming Ye
Despite advances in oncology, the clinical response to treatments, particularly immunotherapy, remains highly variable due to the complex tumor immune microenvironment. While regular exercise is recognized as a supportive intervention to improve patient outcomes, its mechanistic integration into personalized cancer care is limited by a generalized approach to physical activity. In this review, we argue that the heterogeneity of exercise benefits stems from modality-specific immune remodeling. Evidence indicates that distinct exercise types elicit specific "immune stimulation fingerprints". Steady-state aerobic exercise primarily resolves chronic inflammation and promotes immune homeostasis; resistance training preserves the muscle-immune axis, providing critical physical and immune reserves to maintain treatment tolerance; and high-intensity interval training can provoke acute mobilization of effector immune cells. Importantly, the ability of these systemic immune adaptations to enhance treatment response depends heavily on the local tumor immune niche. To bridge the gap between systemic exercise effects and clinical outcomes, we propose the "exercise-immune matching window" model. This framework highlights that improving therapeutic efficacy-and potentially optimizing responses to immunotherapy-requires patient stratification. By aligning specific exercise modalities with the individual's baseline immunophenotype (e.g., chronic inflammation, significant immunosuppression, or immunosenescence) and treatment stage, we can maximize synergistic effects. Ultimately, transitioning from generic exercise recommendations to tailored, immune-directed prescriptions offers a practical strategy to augment comprehensive cancer management.

19 October 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JWJing Wang
Jing Wang
QXQin Xuan
Qin Xuan
ZYZhenyu Yang
Zhenyu Yang
YWYang Wu
Yang Wu
YXYushen Xu
Yushen Xu
MDMei Du
Mei Du
This article provides a narrative review of selected applications of orthopedic robotics in cancer surgery, focusing on musculoskeletal tumor resection, relevant technical developments, and implications for postoperative rehabilitation. Orthopedic robotic technology has evolved continuously, with advances in image guidance, instrument positioning, and operative planning. Robotic assistance may improve the reproducibility of complex osteotomies and reconstruction, but technical accuracy should be distinguished from demonstrated oncologic or functional benefit. Current evidence includes experimental models, case reports, and navigation-assisted series, which do not establish that robotic surgery reduces recurrence or accelerates recovery after orthopedic tumor surgery. Beyond intraoperative applications, artificial intelligence and digital rehabilitation platforms offer potential ways to use surgical data, baseline function, and activity measures to inform individualized rehabilitation and follow-up. Rehabilitation robots, including exoskeletons, represent a separate technology whose suitability and benefits require evaluation in specific patient populations. Integration of these approaches into orthopedic oncology remains a direction for clinical research. Ethical and legal challenges, cost-effectiveness, and unequal access also require consideration. This review highlights the potential of orthopedic robotics while identifying the need for comparative studies of resection margins, long-term tumor control, functional recovery, and quality of life.